Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Dan Ayers"'
Autor:
Satya Das, G. Dan Ayers, Jennifer Whisenant, Anwaar Saeed, Edward Kim, Vaia Florou, George Yacoub, Percy Ivy, Charles Kunos, Jordan Berlin
Publikováno v:
Molecular Cancer Therapeutics. 20:P032-P032
Background: Nearly 50% of patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma possess somatic TP53 mutations, with most mutations falling within exons 2 or 4-11. Though the presence of TP53 mutations has historically been co
Autor:
Nipun B. Merchant, Jordan Berlin, Naoko Takebe, Lori R. Arlinghaus, Laura W. Goff, Thomas E. Yankeelov, Jennifer G. Whisenant, G. Dan Ayers, Emily Chan, Dana Backlund Cardin
Publikováno v:
Investigational New Drugs. 36:442-450
Pancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (
Autor:
Rajiv Agarwal, Vicki L. Keedy, Elizabeth Kaiser, Deborah Wallace, Elizabeth J. Davis, G. Dan Ayers
Publikováno v:
Journal of Clinical Oncology. 39:11559-11559
11559 Background: The feasibility and utility of wearable devices is unknown in sarcoma patients (pts). Objective assessment of activity level, body composition, and PROs facilitate understanding of the tolerability and toxicity of cancer treatment.
Autor:
Tiffany Hickman, Anna Fisher, Kristen K. Ciombor, Cathy Eng, Robert J. Coffey, Allison S. Cohen, Laura W. Goff, Satya Das, Jordan Berlin, Gary T. Smith, Dana Backlund Cardin, G. Dan Ayers, Jennifer G. Whisenant, Adria C. Payne, H. Charles Manning
Publikováno v:
Cancer Research. 80:4260-4260
Background: Gln metabolism plays a critical role in cancer. In CRC, the epidermal growth factor receptor (EGFR) and Gln cooperate to provide signal transduction and fuel for mitogen activated protein kinase-dependent cell growth. Our preclinical data
Autor:
Chanjuan Shi, Jill Gilbert, Jennifer G. Whisenant, Dana Backlund Cardin, Kimberly B. Dahlman, Jordan Berlin, G. Dan Ayers
Publikováno v:
Journal of Clinical Oncology. 38:797-797
797 Background: SBA is rare and often grouped with, and treated like, large intestinal adenocarcinomas. However, SBA has a very different microenvironment and could respond differently to the same therapies, potentially lowering efficacy. Also no sta
Autor:
Williams, Carly Bess, Nebhan, Caroline A., Yang, Jinming, Starnes, Lauren S., Yan, Chi, Vilgelm, Anna E., Chen, Sheau-Chiann, Dan Ayers, Gregory, Abramson, Vandana, Mayer, Ingrid A., Richmond, Ann
Publikováno v:
Breast Cancer Research & Treatment; Nov2020, Vol. 184 Issue 2, p357-364, 8p
Autor:
Andrew Scott Morris, Qi Liu, Sunil K. Geevarghese, Norman Koglin, M. Kay Washington, Dan Ayers, Andrew W. Stephens, Ronald C. Walker, H. Charles Manning, Jason M. Williams, Gina Kavanaugh, Yu Shyr, Michael L. Nickels
Purpose Non-invasive imaging is central to hepatocellular carcinoma (HCC) diagnosis; however, conventional modalities are limited by smaller tumors and other chronic diseases that are often present in patients with HCC, such as cirrhosis. This pilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c79959818e9353ea445847bf8398ad61
https://europepmc.org/articles/PMC5641676/
https://europepmc.org/articles/PMC5641676/
Autor:
Myrick C. Shinall, Harold N. Lovvorn, Wallace W. Neblett, Barry Berch, Pinki K. Prasad, Zhiguo Zhao, James A. O'Neill, Dan Ayers, Melissa A. Hilmes
Publikováno v:
Journal of Pediatric Surgery. 45:121-129
Hepatoblastoma is commonly unresectable at presentation, necessitating induction chemotherapy before definitive resection. To refine the paradigm for timing of resection, we questioned whether a plateau in hepatoblastoma responsiveness to neoadjuvant
Autor:
Bart Barlogie, K. R. Desikan, Dan Ayers, John Crowley, Sundar Jagannath, David S. Siegel, Jayesh Mehta, D. Spoon, D. Dhodapkar, Guido Tricot, Joshua Epstein, Bruce Cheson, Jeffery R. Sawyer, David H. Vesole, J. Cromer, Elias Anaissie, Seema Singhal, S. Naucke, A. Fassas, S Mattox, Nikhil C. Munshi
Publikováno v:
Blood. 93:55-65
Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) with symptomatic multiple myeloma were enrolled in a program that used a series of
Autor:
Cardin, Dana B., Goff, Laura W., Chan, Emily, Whisenant, Jennifer G., Dan Ayers, G., Takebe, Naoko, Arlinghaus, Lori R., Yankeelov, Thomas E., Berlin, Jordan, Merchant, Nipun
Publikováno v:
Investigational New Drugs; Jun2018, Vol. 36 Issue 3, p442-450, 9p